Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and
pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.